Clinical characteristics depending on detection of marker chromosomes, chromothripsis, and ring chromosome groups
| . | Group 1 marker chr. pos. chromothripsis pos. (n = 18)* . | Group 2 marker chr. pos. chromothripsis neg. (n = 31) . | P value† group 1 vs 2 . | Group 3 ring chr. pos. (n = 7)* . | Group 4 control group (complex aberrant w/o marker, ring, dm, der) (n = 34) . |
|---|---|---|---|---|---|
| Clinical parameters | |||||
| Age, y (median, range) | 58 (35-76) | 58 (18-77) | 1.0 | 68 (49-78) | 47 (18-75) |
| Gender (male/female) | 8/10 | 17/14 | 1.0 | 4/3 | 18/16 |
| FAB (0/1/2/4,5/6) | 1/5/4/5/3 | 3/6/11/10/1 | 1.0 | 0/0/4/2/1 | 0/14/3/15/0 |
| Prior MDS (no./N) | 2/17 (11.8%) | 5/31 (16.1%) | 1.0 | 0/6 (0%) | 2/34 (5.9%) |
| Leukocytes, /nL (median, range) | 8.5 (1.6-171.3) | 19.4 (0.6-159.8) | 1.0 | 3.8 (2.5-148.6) | 26.5 (0.4-212.0) |
| LDH, U/mL (median, range) | 716 (182-4160) | 518 (165-5489) | 1.0 | 207 (118-849) | 480 (27-3438) |
| Cytogenetic parameters | |||||
| Complex ab. (≥4) (no./N) | 18/18 (100%) | 20/31 (64.5%) | .04 | 5/7 (71.4%) | 34/34 (100%) |
| Monosomal (no./N) | 16/18 (88.9%) | 14/31 (45.2%) | .04 | 5/7 (71.4%) | 9/34 (26.5%) |
| Subclone formation (no./N) | 16/18 (88.9%) | 16/31 (51.6%) | .13 | 4/7 (57.1%) | 25/34 (73.5%) |
| Abnl(5q) (no./N) | 11/17 (64.7%) | 12/31 (38.7%) | 1.0 | 5/7 (71.4%) | 6/34 (17.6%) |
| Abnl(7q) (no./N) | 8/17 (47.1%) | 10/31 (32.3%) | 1.0 | 1/7 (14.3%) | 5/34 (14.7%) |
| Abn(17q) (no./N) | 9/18 (50.0%) | 5/31 (16.1%) | .20 | 2/7 (28.6%) | 5/34 (14.7%) |
| Number markers (median, range) | 2 (1-11) | 1 (1-7) | .01 | 0 (0-11) | 0 (0-0) |
| Derivate chromosome (no./N) | 8/18 (44.4%) | 5/31 (16.1%) | .41 | 2/7 (28.6%) | 0/34 (0%) |
| Remission status | |||||
| CR+CRi | 2/16 (12.5%) | 10/31 (32.3%) | .18 | 2/7 (28.6%) | 10/34 (29.4%) |
| . | Group 1 marker chr. pos. chromothripsis pos. (n = 18)* . | Group 2 marker chr. pos. chromothripsis neg. (n = 31) . | P value† group 1 vs 2 . | Group 3 ring chr. pos. (n = 7)* . | Group 4 control group (complex aberrant w/o marker, ring, dm, der) (n = 34) . |
|---|---|---|---|---|---|
| Clinical parameters | |||||
| Age, y (median, range) | 58 (35-76) | 58 (18-77) | 1.0 | 68 (49-78) | 47 (18-75) |
| Gender (male/female) | 8/10 | 17/14 | 1.0 | 4/3 | 18/16 |
| FAB (0/1/2/4,5/6) | 1/5/4/5/3 | 3/6/11/10/1 | 1.0 | 0/0/4/2/1 | 0/14/3/15/0 |
| Prior MDS (no./N) | 2/17 (11.8%) | 5/31 (16.1%) | 1.0 | 0/6 (0%) | 2/34 (5.9%) |
| Leukocytes, /nL (median, range) | 8.5 (1.6-171.3) | 19.4 (0.6-159.8) | 1.0 | 3.8 (2.5-148.6) | 26.5 (0.4-212.0) |
| LDH, U/mL (median, range) | 716 (182-4160) | 518 (165-5489) | 1.0 | 207 (118-849) | 480 (27-3438) |
| Cytogenetic parameters | |||||
| Complex ab. (≥4) (no./N) | 18/18 (100%) | 20/31 (64.5%) | .04 | 5/7 (71.4%) | 34/34 (100%) |
| Monosomal (no./N) | 16/18 (88.9%) | 14/31 (45.2%) | .04 | 5/7 (71.4%) | 9/34 (26.5%) |
| Subclone formation (no./N) | 16/18 (88.9%) | 16/31 (51.6%) | .13 | 4/7 (57.1%) | 25/34 (73.5%) |
| Abnl(5q) (no./N) | 11/17 (64.7%) | 12/31 (38.7%) | 1.0 | 5/7 (71.4%) | 6/34 (17.6%) |
| Abnl(7q) (no./N) | 8/17 (47.1%) | 10/31 (32.3%) | 1.0 | 1/7 (14.3%) | 5/34 (14.7%) |
| Abn(17q) (no./N) | 9/18 (50.0%) | 5/31 (16.1%) | .20 | 2/7 (28.6%) | 5/34 (14.7%) |
| Number markers (median, range) | 2 (1-11) | 1 (1-7) | .01 | 0 (0-11) | 0 (0-0) |
| Derivate chromosome (no./N) | 8/18 (44.4%) | 5/31 (16.1%) | .41 | 2/7 (28.6%) | 0/34 (0%) |
| Remission status | |||||
| CR+CRi | 2/16 (12.5%) | 10/31 (32.3%) | .18 | 2/7 (28.6%) | 10/34 (29.4%) |